The prognostic value of morphologic findings for lung squamous cell carcinoma patients

Gürel, Duygu; Ulukuş, Çağnur; Karaçam, Volkan; Ellıdokuz, Hülya; Umay, Cenk; Öztop, İlhan; Sarıoğlu, Sülen

doi:10.1016/j.prp.2015.10.006

Cited by 15 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histological tumor necrosis is a known biomarker predicting poor prognosis in lung SCCs [21–24], but tumor necrosis on CT scans had no impact in our study. Instead, the heterogenous enhancement reflecting intratumoral neovascularization was correlated with poor OS.…”

Section: Discussioncontrasting

confidence: 61%

Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung

Lee

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

ObjectiveLittle is known about prognostic factors for lung squamous cell carcinoma (SCC). We aimed to explore radiologic and clinical factors affecting prognosis and to compare the prognosis of both central and peripheral lung SCCs.Materials and methodsRadiologic, clinical, and pathologic profiles of surgically confirmed SCCs from 382 patients were retrospectively reviewed. Tumor location, enhancement, necrosis, the presence of obstructive pneumonitis/atelectasis and underlying lung disease were evaluated on chest CT examination. Age, pulmonary function, tumor marker, and cancer stage were also assessed. Univariate and multivariate Cox regression analyses were performed to identify any correlation to overall survival (OS) and disease-free survival (DFS). Hazard rate estimation and competing risk analysis were done to evaluate recurrence pattern.ResultsThe median follow-up period was 56.2 months. Tumors were located centrally in 230 patients (60.2%) and peripherally in 152 patients (39.8%). Age (p = 0.002, hazard ratio [HR] 1.03, 95% confidence interval [CI] = [1.01, 1.06]) and interstitial lung abnormalities (ILAs) (p<0.001, HR 5.41, 95% CI = [3.08, 9.52]) were associated with poor OS on multivariate analysis. ILAs also had a strong association to DFS (p<0.001, HR 4.25, 95% CI = [3.08, 9.52]). Central cancers had two peaks of local recurrence development at 15 and 60 months after surgery, and peripheral tumors showed rising curves for metastasis development at 60 months.ConclusionsCT-determined ILAs are a strong biomarker predicting poor outcome. Prognosis may not vary according to tumor location, but the two groups exhibited different recurrence patterns.

show abstract

Section: Discussioncontrasting

confidence: 61%

Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung

Lee

et al. 2019

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Lung cancer remains one of the most common causes of cancer-related deaths all over the world, with over 25% of all cancer-related deaths in both male and female [ 1 – 6 ]. Lung cancer includes two main histological categories: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [ 7 – 4 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma

Tang

Chen

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) expression profile signature for survival assessment in lung squamous cell carcinoma (LUSC) are largely inconsistent due to distinct detecting approaches and small sample size. Systematic and integrative investigation of RNA-Seq based data from The Cancer Genome Atlas (TCGA) herein was performed to determine candidate lncRNAs for prognosis evaluation of LUSC. A total of 60483 genes, including 7589 lncRNAs were assessed in a cohort including 478 LUSC cases with follow-up data. Firstly, 4225 differentially expressed lncRNAs were obtained via R packages. Next, univariate and multivariate Cox proportional hazards regression revealed that 41 lncRNAs were closely related to the survival of LUSC. Finally, lncRNA based prognosis index (PI) could predict overall survival of LUSC with high accuracy (AUC = 0.652, CI: 0.598, 0.705), PI = expCYP4F26P*βCYP4F26P+expRP11-108M12.3*βRP11-108M12.3+expRP11-38M8.1*βRP11-38M8.1+expRP11-54H7.4*βRP11-54H7.4+expZNF503-AS1*βZNF503-AS1. Furthermore, it was confirmed that the five-lncRNA signature could act as an independent prognostic indicator for LUSC (HR = 2.068, p < 0.001 with univariate analysis, HR = 1.928, p = 0.038 with multivariate). Besides, we constructed a weighted gene co-expression network analysis (WGCNA) of key lncRNA RP11-54H7.4 according to the p-value of related genes’ weight. This study provides a RNA-Seq based prognostic signature with five lncRNAs for further clinical application to LUSC patients.

show abstract

“…Outcome of RFS was reported in seven studies [ 15 – 21 ], and OS was reported in eight studies [ 14 – 19 , 21 , 22 ]. In two of the included studies [ 16 , 22 ], univariate analyses were performed to evaluate the association between TSR and survival outcome, while in the other seven studies [ 14 , 15 , 17 – 21 ], multivariate analyses were applied with the adjustment of potential factors such as age, sex, smoking, tumor size, stage, grade, and adjuvant therapy. Table 2 shows the summarized details of study quality evaluation.…”

Section: Resultsmentioning

confidence: 99%

“…Indeed, a previous meta-analysis showed that higher proportion of stroma in primary cancer tissue was associated with poor prognosis of the patients, although studies with various types of cancer were included and a site-specific association between TSR and survival in patients with solid tumor was suggested [13]. Role of tumor-stroma ratio (TSR) as a predictor of survival in patients with non-small cell lung cancer (NSCLC) remains inconsistent according to previous studies [14][15][16][17][18][19][20][21][22]. Patients with stroma-rich NSCLC were shown to have poor survival in some studies [14,15,17,19,20], but not in others [16,18,21,22].…”

Section: Introductionmentioning

confidence: 99%

Predictive Role of Tumor-Stroma Ratio for Survival of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis

Zhang¹,

Ma²,

Zhang³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Background: Role of tumor-stroma ratio (TSR) as a predictor of survival in patients with non-small cell lung cancer (NSCLC) remains not clear. A systematic review and meta-analysis was conducted to summarize current evidence for the role of TSR in NSCLC.Methods: Relevant cohort studies were retrieved via search of Medline, Embase, and Web of Science databases. The data was combined with a random-effect model by incorporating the between-study heterogeneity. Specifically, subgroup and meta-regression analyses were performed to explore the association between TSR and survival in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC).Results: Nine cohort studies with 2031 patients with NSCLC were eligible for the meta-analysis. Pooled results showed that compared to those stroma-poor tumor, patients with stroma rich NSCLC were associated with worse recurrence-free survival (RFS, hazard ratio [HR] = 1.52, 95% confidence interval [CI]: 1.07 to 2.16, p = 0.02) and overall survival (OS, HR = 1.48, 95% CI: 1.20 to 1.82, p < 0.001). Subgroup analyses showed that stroma-rich tumor may be associated with a worse survival of SCC (HR = 1.89 and 1.47 for PFS and OS), but a possibly favorable survival of AC (HR = 0.28 and 0.69 for PFS and OS). Results of meta-regression analysis also showed that higher proportion of patients with SCC was correlated with higher HRs for RFS (Coefficient = 0.012, p = 0.03) and OS (Coefficient = 0.014, p = 0.02) in the included patients, while higher proportion of patients with AC was correlated with lower HRs for RFS (Coefficient = −0.012, p = 0.03) and OS (Coefficient = −0.013, p = 0.04), respectively.Conclusion: Tumor TSR could be used as a predictor of survival in patients with NSCLC. The relative proportion of patients with SCC/AC in the included NSCLC patients may be an important determinant for the association between TSR and survival in NSCLC. Stroma richness may be a predictor of poor survival in patients with lung SCC, but a predictor of better survival in patients with lung AC.

show abstract

The prognostic value of morphologic findings for lung squamous cell carcinoma patients

Cited by 15 publications

References 41 publications

Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung

Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung

Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma

Predictive Role of Tumor-Stroma Ratio for Survival of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis

Contact Info

Product

Resources

About